Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”), announced today that its Board of Directors (the “Board”) has extended the Section 382 net operating loss ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback